Resources

In this blog, the BIA's Senior Policy and Public Affairs Manager, Dr Emma Lawrence, discusses the life science implications of Lord Darzi's review.

This development will improve clinical trial infrastructure.

Arecor Therapeutics plc (AIM: AREC)today presents positive results from its Phase I clinical trial of AT278.

Company secures additional financing to advance clinical programmes in Immuno-Oncology and Inflammatory bowel disease through to data readout

This year RNID have been chosen as the BIA’s charity partner of the year. This partnership gives us a unique platform to shine the light on the huge opportunities that exist for hearing therapeutics.

Unleashing the potential of digital media in clinical trials: compliance by design

Getting UK clinical trials back on track - This second blog from the BIA conference, ‘The Future of UK Regulation: Driving innovation in the life sciences’, looks at what is being done across the research ecosystem to get commercial clinical trials back on track in the UK.

This is the first of four blogs reporting on the BIA’s sell-out conference, ‘The Future of UK Regulation: Driving innovation in the life sciences’.

CPI is a social enterprise that catalyses’ adoption of advanced technology and manufacturing solutions for healthcare and sustainability innovations. 

Iksuda Therapeutics announces first patient dosed in Phase 1 trial of IKS014 in patients with advanced solid tumours that express HER2

Altasciences is proud to support Alzamend Neuro in advancing their dementia treatment. They have completed a Phase IIa clinical trial in healthy subjects and are continuing to provide support in Alzheimer’s patients.

Verona Pharma announces 12 abstracts accepted by ATS 2023 on additional analyses from its Phase 3 ENHANCE studies with ensifentrine for COPD.

New antibody drug conjugate (ADC) programme unveiled, with demonstration of positive pre-clinical proof of concept for Myricx N-myristoyltransferase inhibitors (NMTi) as a completely novel ADC payload.

We were kindly hosted by Anthony Browne MP in the Terrace Pavilion of the House of Commons for a lunchtime reception where we launched our report ‘Becoming a life sciences superpower’ which includes our recommendations for the Comprehensive Spending Review (CSR) which has been confirmed by the Chancellor to be on the 27 October.  

Clinical trials are an essential part of getting new treatments from lab to patient but during the COVID-19 pandemic, trials for treatments outside of COVID-19 had been heavily disrupted. However, in light of all this immediate disruption there have been claims that the swift action taken to produce a vaccine and the adoption of technology could set a positive precedent for the future of clinical trial research.

Per ICH GCP, Clinical Trial Monitoring is the act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, standard operating procedures (SOPs), GCP, and the applicable regulatory requirement(s).

Big steps forward in the development of vaccines against COVID-19 for the UK today that the BIA and its members have been working towards for months. In a series of announcements the Government has unveiled a number of deals to secure access to 90 million doses of COVID-19 vaccine candidates. To facilitate the development of candidates, a new NHS registry has been set up to help make recruitment into clinical trials run smoothly.

The use of animals in research continues to rank highly in the public consciousness, with a 2018 Ipsos MORI poll showing that three-fifths of people are interested in the methods used by scientists to replace, reduce and refine the use of animals in research (the 3Rs). The UK’s National Centre for the Replacement, Refinement and Reduction of Animals in Research (the NC3Rs) is committed to furthering this goal. Its programme includes a long-standing collaboration with the pharmaceutical industry that has led to changes in company practice and regulatory guidelines.